Trogenix Preclinical Breakthrough in Glioblastoma Paves Way to First-in-Human Trial

New updates have been reported about Trogenix.

Trogenix has published preclinical data in Nature showing complete tumor clearance and durable protection in an aggressive brain cancer model that closely mirrors human glioblastoma, positioning the company for its transition into a clinical-stage oncology business. The study validates Trogenix’s Synthetic Super-Enhancer platform, delivered via AAV vectors to target SOX2- and SOX9-driven networks in glioblastoma stem cells, and supports planned first patient dosing in a Phase I/II trial (ADePT) expected in the second quarter of 2026.

In the preclinical work, a single SSE-based treatment dose eradicated tumors, prevented recurrence, and spared normal brain tissue when tested on fresh patient samples, suggesting a favorable therapeutic window and reduced off-target toxicity risk. The dual-payload construct combines HSV-TK for direct cancer cell killing with IL-12 to stimulate an immune response, effectively turning the tumor into an in situ vaccine and creating long-term immunological memory against glioblastoma.

Chief Scientific Officer and co-founder Professor Steve Pollard said the results demonstrate the potential to achieve what had previously seemed unattainable in GBM: single-agent, single-dose, curative-like responses with sustained protection, reinforcing the company’s focus on hard-hitting, early intervention gene therapy. Backed by Cancer Research UK, BBSRC and a £70 million Series A round completed in October 2025, Trogenix now has capital to advance its GBM asset and broader solid tumor pipeline into the clinic, including programs in hepatocellular carcinoma and colorectal cancer liver metastases.

The spin-out from the University of Edinburgh, incubated by 4BIO Capital and supported by investors such as IQ Capital, Eli Lilly & Co. and Cancer Research Horizons, aims to leverage its Odysseus platform to build a portfolio of potentially curative therapies across aggressive solid tumors. For executives and investors, the Nature publication serves as a critical technical and de-risking milestone that underpins Trogenix’s valuation, supports its clinical development timelines, and could accelerate strategic partnering or future financing as the ADePT trial initiates.